{"id":2,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1002.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for a follow-up visit 3 months later. The patient reports a significant worsening of vision, and repeat imaging confirms that the intraretinal cystic spaces and macular thickening have persisted and slightly progressed despite receiving four consecutive monthly anti-VEGF injections. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","C":"Perform urgent pars plana vitrectomy and epiretinal membrane peeling to relieve traction","D":"Continue the exact same anti-VEGF injection protocol for another three months without changes"},"answer":"A"},"label":"CNV"}
{"id":15,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1015.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity after a period of observation. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":17,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1017.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up. The patient describes a progressive worsening of visual distortion and a significant decline in their central vision since the initial diagnosis. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":46,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1046.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for a routine follow-up evaluation. The patient reports experiencing progressive distortion of straight lines and a noticeable decline in visual acuity since their last visit. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Escalate therapy by adding another medication class or recommending selective laser trabeculoplasty (SLT)","D":"Continue strict observation with lifestyle modifications without any additional testing or intervention"},"answer":"A"},"label":"CNV"}
{"id":62,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1062.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up after initiating a standard loading regimen of anti-VEGF injections. The follow-up OCT reveals complete resolution of the subretinal and intraretinal fluid, and the patient reports stable visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring","B":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":89,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1089.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up 3 months later. The follow-up imaging reveals that the subretinal fluid has persisted without spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":91,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1091.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. Despite undergoing three consecutive anti-VEGF injections, follow-up OCT reveals persistent intraretinal cystic spaces and macular thickening, with no improvement in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":99,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1099.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image is evaluated after a 3-month course of conservative observation. They report a progressive decline in visual acuity, and follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention such as photodynamic therapy (PDT) or focal laser photocoagulation","B":"Initiate an intravitreal anti-VEGF injection regimen followed by a treat-and-extend protocol","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without repeat imaging"},"answer":"A"},"label":"CNV"}
{"id":109,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1109.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":113,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1113.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up evaluation. Initial observation has failed to yield spontaneous improvement, with imaging revealing persistent and worsening subretinal fluid alongside a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":119,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1119.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image presents for follow-up 3 months later. The subretinal fluid persists without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":120,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1120.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. Follow-up imaging reveals that the subretinal fluid has persisted and worsened after 3 months of conservative observation, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":125,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1125.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for evaluation. Despite completing a series of consecutive anti-VEGF injections over the past few months, follow-up OCT imaging reveals that the intraretinal cystic spaces and macular thickening remain refractory, with no significant structural improvement. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Perform repeat OCT imaging to evaluate for recurrent fluid and initiate prompt anti-VEGF retreatment","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":128,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1128.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":132,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1132.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the intraretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Switch to an intravitreal corticosteroid implant or alternative anti-VEGF agent","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":153,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1153.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Over the subsequent months, the subretinal fluid persists without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":167,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1167.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up evaluation. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":171,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1171.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. After multiple consecutive intravitreal anti-VEGF injections, follow-up imaging reveals that the intraretinal cystic spaces and macular thickening remain refractory, and the patient continues to report blurred vision. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the anti-VEGF injection interval and continue proactive monitoring using a Treat-and-Extend protocol","C":"Proceed directly to pars plana vitrectomy and epiretinal membrane peeling","D":"Maintain the exact current anti-VEGF dosing protocol indefinitely without further imaging"},"answer":"A"},"label":"CNV"}
{"id":205,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1205.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":222,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1222.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":230,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1230.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":241,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1241.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up evaluation after undergoing an initial series of anti-VEGF loading injections. The new imaging shows complete resolution of the intraretinal and subretinal fluid, and the patient reports stable visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring (Treat-and-Extend)","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","D":"Continue strict observation with lifestyle modifications without any further injections for the next 12 months"},"answer":"A"},"label":"CNV"}
{"id":279,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1279.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The subretinal fluid persists without any spontaneous resolution after 3 months of conservative observation, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Initiate intravitreal anti-VEGF injections to address the neovascular leakage","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":280,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1280.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":289,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1289.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. The subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity after 3 months of conservative observation. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":293,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1293.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for evaluation 6 months later. Follow-up imaging reveals that the intraretinal fluid and macular edema have completely resolved, and the patient reports stable, improved visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Proceed immediately to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications indefinitely without testing"},"answer":"A"},"label":"CNV"}
{"id":297,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1297.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The subretinal fluid persists without resolution after three months of conservative observation, accompanied by a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":299,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1299.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Complete resolution of intraretinal and subretinal fluid is observed after an initial loading series of injections, and visual acuity has stabilized. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","D":"Continue the current fixed-dose injection schedule indefinitely to prevent any possible recurrence"},"answer":"A"},"label":"CNV"}
{"id":300,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1300.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for a follow-up visit. They describe a progressive worsening of metamorphopsia and a significant decline in their best-corrected visual acuity over the past month. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch immediately to an alternative anti-VEGF agent or consider an intravitreal corticosteroid implant","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling and gas tamponade","D":"Continue strict observation with routine follow-up in 3 months without intervention"},"answer":"A"},"label":"CNV"}
{"id":301,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1301.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image presents for follow-up imaging. They report worsening visual symptoms despite recent treatment, and the scan reveals persistent intraretinal cystic spaces and macular thickening. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":302,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1302.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. Subsequent imaging reveals that despite multiple consecutive anti-VEGF injections, the intraretinal cystic spaces and macular thickening remain refractory or have worsened. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":312,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1312.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":320,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1320.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation after receiving several consecutive intravitreal anti-VEGF injections. Follow-up imaging shows that the intraretinal cystic spaces and macular thickening remain refractory and have failed to improve. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue strict observation with lifestyle modifications without any treatment changes"},"answer":"A"},"label":"CNV"}
{"id":336,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1336.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up evaluation. The patient reports a progressive decline in visual acuity and worsening metamorphopsia despite initial conservative observation. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Proceed with surgical intervention using pars plana vitrectomy and membrane peeling","B":"Initiate intravitreal anti-VEGF injections for recurrent macular edema","C":"Prescribe an intravitreal corticosteroid implant for refractory intraocular inflammation","D":"Continue strict observation and lifestyle modifications for another 6 months"},"answer":"A"},"label":"CNV"}
{"id":346,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1346.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The subretinal fluid has persisted without any spontaneous resolution after 3 months of conservative observation, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":348,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CNV\\cnv_test_1348.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up 3 months later. The patient reports a significant worsening of visual acuity and new onset of metamorphopsia. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CNV"}
{"id":359,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1009.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up after initial observation. They report persistent visual symptoms, and new imaging reveals that the subretinal fluid remains unresolved and the condition has not improved after several months. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention such as photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications indefinitely without further testing"},"answer":"A"},"label":"CSC"}
{"id":360,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1010.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":369,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1019.jpg","vqa":{"question":"The patient returns for a 3-month follow-up evaluation of the pathology demonstrated in this OCT image. The subretinal fluid persists without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Proceed with pars plana vitrectomy and internal limiting membrane peeling","C":"Switch to an alternative anti-VEGF agent or consider an intravitreal corticosteroid implant","D":"Continue strict observation for another 12 months without any diagnostic testing"},"answer":"A"},"label":"CSC"}
{"id":373,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1023.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The subretinal fluid persists and visual acuity continues to decline after 3 months of conservative observation. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":377,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1027.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":381,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1031.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Despite a period of conservative observation, imaging reveals persistent subretinal fluid and worsening visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months"},"answer":"A"},"label":"CSC"}
{"id":391,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1041.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up evaluation. The imaging reveals that despite an initial period of conservative observation, the subretinal fluid persists and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":400,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1050.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for a 3-month follow-up. They report progressive metamorphopsia and a significant drop in visual acuity, with imaging now showing a thickened macula and distorted foveal contour. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate intravitreal anti-VEGF injections or consider focal laser photocoagulation","C":"Perform repeat OCT imaging in 3 months to monitor for spontaneous resolution","D":"Prescribe topical corticosteroids and recommend strict posture modifications"},"answer":"A"},"label":"CSC"}
{"id":401,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1051.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":406,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1056.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up. The subretinal fluid persists and worsens after 3 months of conservative observation, with declining visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":407,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1057.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":409,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1059.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":428,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1078.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up. The patient reports a progressive decline in visual acuity and increasing metamorphopsia over the past few months. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":436,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1086.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up 3 months later. Despite initial conservative management, imaging reveals that the subretinal fluid persists and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":440,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1090.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":453,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1103.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for a follow-up evaluation. The patient reports a significant increase in metamorphopsia (visual distortion) and a notable decline in visual acuity compared to the initial visit. What is the MOST appropriate next step in their management?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Maintain the current exact protocol without change and schedule a follow-up in 6 months"},"answer":"A"},"label":"CSC"}
{"id":462,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1112.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":466,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1116.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":468,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1118.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":475,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1125.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for a follow-up visit. The imaging reveals that the subretinal fluid persists without spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":476,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1126.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":482,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1132.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":511,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1161.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":512,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1162.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. Despite 3 months of conservative observation and lifestyle modifications, follow-up imaging reveals that the subretinal fluid has persisted and worsened, accompanied by a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":531,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1181.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The subretinal fluid persists and worsens after 3 months of conservative observation, with declining visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention such as photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":532,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1182.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":545,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1195.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention such as photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":549,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1199.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up evaluation. After several months of observation, the subretinal fluid persists and visual acuity has progressively declined. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":559,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1209.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Extend the anti-VEGF injection interval with continued proactive monitoring using a treat-and-extend protocol","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":560,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1210.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up after several months of conservative management. New imaging reveals that the subretinal fluid has persisted and worsened, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":568,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1218.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":569,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1219.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image is re-evaluated three months later. Despite conservative management, follow-up imaging reveals that the subretinal fluid has persisted, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Initiate intravitreal anti-VEGF therapy to target occult choroidal neovascularization","C":"Perform immediate pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without further testing"},"answer":"A"},"label":"CSC"}
{"id":571,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1221.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for a 3-month follow-up evaluation. Follow-up imaging reveals that the subretinal fluid has persisted without spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":579,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1229.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":589,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1239.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. After 3 months of conservative observation, follow-up imaging reveals that the subretinal fluid has persisted and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Extend the anti-VEGF injection interval while maintaining the current frequency","C":"Recommend surgical intervention with pars plana vitrectomy and internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without further testing"},"answer":"A"},"label":"CSC"}
{"id":593,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1243.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":607,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1257.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":625,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1275.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for evaluation. Subsequent imaging shows persistent subretinal fluid without spontaneous resolution, accompanied by a progressive decline in visual acuity over a 3-month observation period. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Initiate intravitreal anti-VEGF therapy with a strict monthly injection protocol","C":"Proceed directly to pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":639,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1289.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":649,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1299.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up 3 months later. The imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention such as photodynamic therapy (PDT) or focal laser photocoagulation","B":"Extend the anti-VEGF injection interval with continued proactive monitoring using a Treat-and-Extend protocol","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without additional testing"},"answer":"A"},"label":"CSC"}
{"id":650,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1300.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":655,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1305.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":665,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1315.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":667,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1317.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":671,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1321.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for a follow-up visit after 3 months of conservative observation. The imaging reveals persistent subretinal fluid and a slight worsening of the macular elevation, and the patient reports a progressive decline in their visual acuity. What is the MOST appropriate next step in their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":673,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1323.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up after an initial period of observation. The subretinal fluid has persisted and worsened, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without further imaging"},"answer":"A"},"label":"CSC"}
{"id":679,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1329.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for a 3-month follow-up. Imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":681,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1331.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":689,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1339.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":690,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\CSR\\csr_test_1340.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Initiate intravitreal injections of an anti-VEGF agent or a corticosteroid implant","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"CSC"}
{"id":771,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\DME\\dme_test_1071.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Despite multiple consecutive intravitreal anti-VEGF injections, follow-up imaging reveals persistent intraretinal cystic spaces and worsening macular thickening. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the injection interval to a treat-and-extend regimen and continue monitoring","C":"Initiate strict systemic vascular risk factor management and stroke prevention","D":"Maintain the current exact protocol without change, as further injections are required"},"answer":"A"},"label":"DME"}
{"id":861,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\DME\\dme_test_1161.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image is evaluated after receiving multiple consecutive anti-VEGF injections. Follow-up imaging reveals that the intraretinal cystic spaces and macular thickening remain refractory and have failed to improve. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"DME"}
{"id":866,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\DME\\dme_test_1166.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up. Despite multiple consecutive anti-VEGF injections, imaging reveals persistent intraretinal cystic spaces and worsening macular thickening. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the anti-VEGF injection interval using a treat-and-extend approach","C":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"DME"}
{"id":881,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\DME\\dme_test_1181.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for a scheduled follow-up after multiple consecutive anti-VEGF injections. Follow-up imaging reveals that the intraretinal cystic spaces and macular thickening remain refractory or have worsened despite the current treatment regimen. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"DME"}
{"id":887,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\DME\\dme_test_1187.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. Despite receiving multiple consecutive anti-VEGF injections, follow-up imaging shows that the intraretinal cystic spaces and macular thickening remain refractory or have worsened. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Proceed immediately to pars plana vitrectomy with internal limiting membrane peeling","D":"Continue the exact same anti-VEGF injection protocol without any changes for another 6 months"},"answer":"A"},"label":"DME"}
{"id":905,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\DME\\dme_test_1205.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The patient reports a noticeable increase in visual distortion and a further drop in visual acuity compared to the previous visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Escalate therapy by adding another medication class or recommending selective laser trabeculoplasty (SLT)","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"DME"}
{"id":943,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\DME\\dme_test_1243.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. They report a progressive worsening of metamorphopsia and a significant drop in visual acuity during their last few visits. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","D":"Continue the current observation protocol without any changes for another 6 months"},"answer":"A"},"label":"DME"}
{"id":957,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\DME\\dme_test_1257.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. Despite completing a full loading phase of intravitreal anti-VEGF injections, the follow-up OCT shows persistent intraretinal cystic spaces and macular thickening without significant anatomical improvement. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the anti-VEGF injection interval with continued proactive monitoring using a treat-and-extend protocol","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","D":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling"},"answer":"A"},"label":"DME"}
{"id":962,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\DME\\dme_test_1262.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up evaluation. The patient reports a progressive decline in visual acuity and worsening metamorphopsia. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Proceed directly to intravitreal corticosteroid implant therapy or alternative anti-VEGF agent","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"DME"}
{"id":984,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\DME\\dme_test_1284.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. Despite undergoing multiple consecutive anti-VEGF injections, the intraretinal cystic spaces and macular thickening remain refractory. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","D":"Maintain the current exact protocol without any changes for another six months"},"answer":"A"},"label":"DME"}
{"id":990,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\DME\\dme_test_1290.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. Intraretinal cystic spaces and macular thickening remain refractory or worsen despite multiple consecutive anti-VEGF injections. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","C":"Recommend surgical intervention with pars plana vitrectomy and membrane peeling","D":"Continue the exact same intravitreal anti-VEGF injection protocol and observe for another 3 months"},"answer":"A"},"label":"DME"}
{"id":999,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\DME\\dme_test_1299.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up after completing an initial loading phase of intravitreal anti-VEGF injections. The follow-up imaging reveals that the intraretinal cystic spaces and macular thickening remain refractory, with no significant anatomical improvement observed. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the anti-VEGF injection interval with continued proactive monitoring using a treat-and-extend approach","C":"Perform an emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Maintain the current exact anti-VEGF protocol and schedule routine observation for 6 months"},"answer":"A"},"label":"DME"}
{"id":1026,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\DME\\dme_test_1326.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. They report progressive worsening of vision despite receiving multiple consecutive anti-VEGF injections. Current imaging shows persistent intraretinal cystic spaces and macular thickening. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Proceed to pars plana vitrectomy with epiretinal membrane peeling","D":"Continue the current anti-VEGF treatment protocol unchanged"},"answer":"A"},"label":"DME"}
{"id":1067,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\MH\\mh_test_1017.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Extend the anti-VEGF injection interval while maintaining the current proactive monitoring protocol","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"MH"}
{"id":1092,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\MH\\mh_test_1042.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up evaluation. The patient reports a progression in visual distortion and a significant decline in visual acuity compared to their previous visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Maintain the current exact protocol without change and continue routine observation"},"answer":"A"},"label":"MH"}
{"id":1214,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\MH\\mh_test_1164.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Maintain regular outpatient follow-up to monitor visual recovery and structural stabilization","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"MH"}
{"id":1228,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\MH\\mh_test_1178.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. The patient reports a progressive increase in vision distortion and a significant decline in visual acuity, and examination reveals an increase in the retinal wrinkling and thickening observed previously. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Maintain regular outpatient follow-up to monitor visual recovery and structural stabilization","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"MH"}
{"id":1239,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\MH\\mh_test_1189.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for evaluation. They report progressive metamorphopsia and a significant drop in visual acuity compared to previous visits. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate prompt anti-VEGF retreatment to evaluate for recurrent macular edema","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"MH"}
{"id":1258,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\MH\\mh_test_1208.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. The patient reports a significant worsening of their central visual acuity and progressive distortion of vision compared to their baseline visit. What is the MOST appropriate next step in their management?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Extend the treatment interval and maintain strict observation with routine annual comprehensive eye examinations","D":"Escalate therapy by adding another medication class or recommending selective laser trabeculoplasty (SLT)"},"answer":"A"},"label":"MH"}
{"id":1338,"image_path":"E:\\OCT\\OCT-Bench\\OCT-C8\\test\\MH\\mh_test_1288.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"MH"}
{"id":1410,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\DME\\dme_1310005_3.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up. Despite multiple consecutive anti-VEGF injections, the intraretinal cystic spaces and macular thickening remain refractory and worsen. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the anti-VEGF injection interval with continued proactive monitoring using a Treat-and-Extend regimen","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 6 months without testing"},"answer":"A"},"label":"DME"}
{"id":1433,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\DME\\dme_2757902_2.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up after multiple consecutive anti-VEGF injections. Repeat imaging reveals that the intraretinal cystic spaces and macular thickening remain refractory and have worsened. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the current anti-VEGF injection interval to every 12 weeks with continued proactive monitoring","C":"Recommend immediate surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Maintain the exact current injection protocol without any changes and reassess in 6 months"},"answer":"A"},"label":"DME"}
{"id":1447,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\DME\\dme_3676374_1.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for a scheduled follow-up after an initial series of treatments. Repeat imaging reveals that the intraretinal cystic spaces and macular thickening remain refractory, showing minimal structural improvement despite multiple consecutive monthly injections. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the current anti-VEGF injection interval and maintain proactive treat-and-extend monitoring","C":"Perform emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Discontinue all intravitreal therapies and proceed to routine annual comprehensive eye examinations"},"answer":"A"},"label":"DME"}
{"id":1510,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\DME\\dme_7335353_1.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image is re-evaluated after undergoing multiple consecutive intravitreal anti-VEGF injections. The follow-up imaging reveals that the intraretinal cystic spaces and macular thickening remain refractory and have not significantly improved. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the current anti-VEGF injection interval with continued proactive monitoring","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Maintain the current exact protocol without change for another 12 months"},"answer":"A"},"label":"DME"}
{"id":1531,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\DME\\dme_8916465_1.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for evaluation 6 months later. Follow-up imaging reveals that the intraretinal cystic spaces and macular thickening remain refractory despite multiple consecutive anti-VEGF injections. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","D":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling"},"answer":"A"},"label":"DME"}
{"id":1536,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\DME\\dme_9057060_1.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for evaluation after undergoing initial loading injections. Follow-up imaging reveals that the intraretinal cystic spaces and macular thickening remain refractory and show minimal improvement. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the anti-VEGF injection interval with continued proactive monitoring using a treat-and-extend regimen","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Discontinue all active treatment and continue strict observation with routine annual examinations"},"answer":"A"},"label":"DME"}
{"id":1548,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_1043186_1.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. They report a progressive increase in metamorphopsia and a significant drop in visual acuity since the initial diagnosis. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Proceed with pars plana vitrectomy, gas tamponade, and internal limiting membrane peeling","D":"Maintain the current exact protocol without change and schedule a follow-up in 12 months"},"answer":"A"},"label":"ERM"}
{"id":1550,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_1225803_1.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up. The patient reports a noticeable progression in metamorphopsia and a significant decrease in visual acuity since their initial visit. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt retreatment if present","D":"Maintain strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1551,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_1225803_2.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up evaluation. The patient reports a significant progression of visual symptoms, specifically new-onset metamorphopsia and a measurable decline in visual acuity since their baseline examination. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1552,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_1225803_3.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up evaluation. The patient reports a progressive increase in metamorphopsia and a significant decline in visual acuity compared to the baseline visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management","D":"Continue routine annual comprehensive eye examinations and standard wellness monitoring"},"answer":"A"},"label":"ERM"}
{"id":1553,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_1225803_4.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up evaluation. Over recent months, the patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate a loading phase of intravitreal anti-VEGF injections followed by a treat-and-extend regimen","C":"Escalate therapy by adding another medication class or recommending selective laser trabeculoplasty (SLT)","D":"Maintain strict observation with the current exact protocol for another 12 months"},"answer":"A"},"label":"ERM"}
{"id":1554,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_1225803_5.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up. Over recent months, they report a progressive worsening of metamorphopsia and a significant decline in visual acuity, despite initially having stable symptoms. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Coordinate long-term care focusing on strict systemic vascular risk factor management","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1555,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_1484824_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. The patient reports a progressive worsening of metamorphopsia and a significant decline in visual acuity over the past several months. What is the MOST appropriate next step in their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging and initiate prompt anti-VEGF retreatment if recurrent edema is present","C":"Proceed directly to intravitreal corticosteroid implant therapy for recalcitrant macular edema","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1556,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_1484824_2.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up evaluation. They report a progressive increase in visual distortion and a significant drop in visual acuity since their initial presentation. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1558,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_1811863_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. The patient describes a progressive worsening of metamorphopsia and a significant drop in visual acuity during subsequent follow-up visits. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Proceed directly to emergency scleral buckling and pneumatic retinopexy","D":"Continue strict observation with lifestyle modifications for another 12 months without further testing"},"answer":"A"},"label":"ERM"}
{"id":1559,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_1811863_2.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up evaluation. During the visit, the patient describes a progressive increase in metamorphopsia (visual distortion) and reports a significant drop in visual acuity compared to their baseline. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1560,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_1835147_1.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Over the subsequent months, the patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","D":"Continue strict observation with lifestyle modifications without further intervention"},"answer":"A"},"label":"ERM"}
{"id":1563,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_1980479_2.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The patient now describes progressive metamorphopsia and a significant drop in visual acuity compared to prior visits. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1564,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_1980479_3.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for evaluation and reports a progressive increase in visual distortion and a significant decline in visual acuity since the initial visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1565,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_2073089_1.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. They report progressively worsening metamorphopsia and a significant decline in visual acuity compared to their baseline examination. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1566,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_2073089_2.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for a routine follow-up visit. During the interval between visits, they describe a progressive worsening of metamorphopsia and a significant drop in their visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","D":"Continue routine annual comprehensive eye examinations and standard wellness monitoring"},"answer":"A"},"label":"ERM"}
{"id":1569,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_2166457_2.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for a routine follow-up visit. They describe a significant progression of metamorphopsia and a recent, notable drop in their visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate prompt anti-VEGF retreatment to evaluate and treat for recurrent macular edema","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Maintain the current exact protocol without change as spontaneous resolution is still highly likely"},"answer":"A"},"label":"ERM"}
{"id":1570,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_2310962_1.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for evaluation. The patient reports progressive worsening of visual acuity and increasing difficulty with daily tasks. Follow-up imaging confirms structural changes consistent with the progression of the baseline condition. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate prompt anti-VEGF retreatment to address recurrent macular edema","C":"Prescribe intensive topical prostaglandin analogs and beta-blockers for intraocular pressure control","D":"Continue observation with current conservative regimen for another year"},"answer":"A"},"label":"ERM"}
{"id":1572,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_2310962_3.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for a 1-year follow-up. They report a progressive increase in metamorphopsia and a significant decline in visual acuity, which has begun to impact their daily reading. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications and routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1574,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_2400030_2.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1575,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_2507788_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation several months later. They report a significant increase in visual distortion and a substantial decline in their visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate an urgent intravitreal injection of an anti-VEGF agent or corticosteroid","C":"Proceed directly to emergency retinal laser photocoagulation to seal the retinal defect","D":"Continue conservative observation with a repeat OCT scheduled in 12 months"},"answer":"A"},"label":"ERM"}
{"id":1578,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_2548202_2.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up. They report progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1579,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_2557141_1.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The patient describes progressive metamorphopsia (distortion) and a significant drop in visual acuity since the initial visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Initiate systemic vascular risk factor management and strict stroke prevention","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1580,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_2584110_1.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient describes progressive metamorphopsia (distortion) and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Escalate therapy by adding another medication class or recommending selective laser trabeculoplasty (SLT)","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1582,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_2635301_2.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The patient describes a progressive worsening of metamorphopsia and a significant decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1583,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_2933504_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 6 months later. The patient reports a progressive worsening of metamorphopsia and a significant decline in visual acuity, despite the absence of a full-thickness macular hole. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging and initiate prompt anti-VEGF retreatment for recurrent macular edema","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue with routine annual comprehensive eye examinations and standard wellness monitoring"},"answer":"A"},"label":"ERM"}
{"id":1584,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_3300105_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. The patient reports a progressive worsening of metamorphopsia and a significant decline in visual acuity since the initial visit. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1586,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_3527083_1.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The patient describes progressive metamorphopsia and a significant drop in visual acuity during subsequent visits. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1587,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_3575502_1.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. They report progressive metamorphopsia (distortion) and a significant drop in visual acuity compared to their baseline visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","C":"Initiate prompt intravitreal anti-VEGF retreatment and perform repeat OCT imaging to evaluate for recurrent macular edema","D":"Continue with routine annual comprehensive eye examinations and standard wellness monitoring"},"answer":"A"},"label":"ERM"}
{"id":1588,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_3575502_2.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. They report a recent and significant increase in metamorphopsia and a subjective drop in visual acuity, with clinical examination confirming progressive focal thickening and distortion of the foveal contour. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Immediately escalate systemic vascular risk factor management and initiate strict blood pressure control","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1589,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_3575502_3.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. They report a progressive increase in metamorphopsia and a significant decline in visual acuity compared to the initial visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1590,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_3849671_1.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image presents for follow-up. They report a progressive increase in visual distortion (metamorphopsia) and a significant decline in visual acuity since the baseline examination. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate monthly intravitreal anti-VEGF injections to address the structural changes","C":"Perform photodynamic therapy (PDT) to target the focal area of thickening","D":"Continue routine observation with annual comprehensive eye examinations and standard wellness monitoring"},"answer":"A"},"label":"ERM"}
{"id":1591,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_3849671_2.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image presents for follow-up and reports a progressive increase in metamorphopsia and a significant decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Administer an intravitreal corticosteroid implant to reduce macular thickening and cystic spaces","D":"Maintain strict observation and continue routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1592,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_4014066_1.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up, reporting a progressive increase in metamorphopsia and a significant decline in visual acuity compared to prior visits. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Switch to an intravitreal corticosteroid implant therapy to address the worsening condition","D":"Maintain the current exact protocol without change and discharge the patient for routine annual monitoring"},"answer":"A"},"label":"ERM"}
{"id":1593,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_4247823_1.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. The patient describes progressive metamorphopsia (distortion) and a significant drop in visual acuity since the baseline visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1594,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_4407796_1.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image presents for a follow-up visit. They report a progressive increase in metamorphopsia and a significant decline in visual acuity since the initial baseline examination. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Extend the anti-VEGF injection interval with continued proactive monitoring","D":"Maintain strict observation with lifestyle modifications without altering the current plan"},"answer":"A"},"label":"ERM"}
{"id":1595,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_4407796_2.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling for a suspected macular hole","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1596,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_4409880_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","D":"Continue strict observation for another 12 months without further testing"},"answer":"A"},"label":"ERM"}
{"id":1598,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_4409880_3.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up, reporting a progressive increase in visual distortion and a significant decline in visual acuity compared to the initial visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Escalate therapy by adding another medication class or recommending selective laser trabeculoplasty","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1599,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_4523545_1.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient describes progressive metamorphopsia (distortion) and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Escalate therapy by adding another medication class, recommending selective laser trabeculoplasty (SLT), or planning incisional surgery","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Maintain the current exact protocol without any changes or further intervention"},"answer":"A"},"label":"ERM"}
{"id":1600,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_4523545_2.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. The patient reports that over the past several months, they have experienced progressive worsening of central visual acuity and increasing difficulty reading due to distorted vision. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Escalate therapy by initiating a loading dose of intravitreal anti-VEGF injections","C":"Initiate aggressive intraocular pressure reduction and refer for emergency optic nerve decompression","D":"Continue strict observation and reassurance, monitoring only for another 12 months"},"answer":"A"},"label":"ERM"}
{"id":1603,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_4816407_2.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for a follow-up visit reporting a significant increase in visual distortion and a decline in visual acuity compared to their baseline. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1608,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_4988592_1.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for a routine follow-up. The patient reports a progressive worsening of visual distortion and a significant decline in visual acuity compared to the baseline examination. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1609,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_4988592_2.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1610,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_5110347_1.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for evaluation. During subsequent follow-up visits, the patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Proceed with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1612,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_5110347_3.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for evaluation. They now report a progressive increase in central visual distortion and a significant decline in visual acuity compared to their baseline examination. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Proceed directly to intravitreal corticosteroid implant therapy for refractory edema","D":"Continue strict observation with no changes to the current management protocol"},"answer":"A"},"label":"ERM"}
{"id":1613,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_5110347_4.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1614,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_5110347_5.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. They report progressive metamorphopsia (distortion) and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1615,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_5110347_6.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1616,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_5110347_7.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Continue strict observation with lifestyle modifications for another 12 months without testing","D":"Switch to an intravitreal corticosteroid implant or alternative anti-VEGF agent"},"answer":"A"},"label":"ERM"}
{"id":1618,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_5438495_2.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation after a period of observation. They report a progressive increase in visual distortion and a significant drop in visual acuity compared to their baseline examination. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate intravitreal anti-VEGF injections or consider switching to a corticosteroid implant","C":"Proceed with focal laser photocoagulation or photodynamic therapy (PDT)","D":"Continue routine observation and standard wellness monitoring without any intervention"},"answer":"A"},"label":"ERM"}
{"id":1621,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_5616388_2.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. The patient reports a significant, progressive increase in metamorphopsia and a substantial decline in visual acuity since the baseline examination. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate a loading phase of intravitreal anti-VEGF injections followed by a treat-and-extend protocol","C":"Proceed with observation for another 12 months to allow potential spontaneous resolution","D":"Administer an intravitreal corticosteroid implant to reduce the observed retinal thickening"},"answer":"A"},"label":"ERM"}
{"id":1622,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_5616388_3.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. Over the ensuing months, the patient reports progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 6 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1623,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_5791022_1.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. They report progressive metamorphopsia and a significant decline in visual acuity, with repeat imaging showing structural distortion. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1624,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_5813011_1.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The patient describes a progressive increase in metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1625,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_5896471_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. During subsequent follow-up visits, the patient describes progressive metamorphopsia (distortion) and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1627,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_5951557_1.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up. The patient reports a progressive worsening of visual acuity and increasing metamorphopsia. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1629,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_5958881_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. The patient reports a progressive worsening of metamorphopsia and a significant decline in visual acuity since the initial visit. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Escalate therapy by adding another IOP-lowering medication class or recommending selective laser trabeculoplasty","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1630,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_5958881_2.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up, reporting progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Escalate therapy by adding another medication class or recommending selective laser trabeculoplasty","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1631,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_5990264_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation after several months of observation. They report a progressive increase in visual distortion and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Escalate therapy by adding a second IOP-lowering medication or recommending selective laser trabeculoplasty","C":"Initiate prompt anti-VEGF retreatment to manage recurrent macular edema","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1632,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_6081919_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. Over the subsequent months, the patient describes progressive metamorphopsia and a significant decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Coordinate long-term care focusing on strict systemic vascular risk factor management","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1634,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_6189656_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up evaluation. They describe a progressive worsening of metamorphopsia and a significant decline in their visual acuity compared to the baseline visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Administer an intravitreal corticosteroid implant or switch to an alternative anti-VEGF agent","C":"Perform urgent photodynamic therapy (PDT) to reduce fluid accumulation","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1635,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_6189656_2.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up with progressive complaints of worsening metamorphopsia and a decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Escalate therapy by adding another medication class or recommending selective laser trabeculoplasty","C":"Continue strict observation with lifestyle modifications for another 12 months without testing","D":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation"},"answer":"A"},"label":"ERM"}
{"id":1636,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_6189656_3.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. They report a recent significant drop in visual acuity and increasing metamorphopsia. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Escalate therapy by adding another medication class, recommending selective laser trabeculoplasty (SLT), or planning incisional surgery","C":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1639,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_6193565_2.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up, describing a progressive worsening of metamorphopsia and a significant decline in visual acuity since their last visit. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Administer an intravitreal corticosteroid implant to reduce retinal thickening and inflammation","D":"Maintain the current strict observation protocol with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1640,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_6220988_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. The patient describes a progressive worsening of metamorphopsia and a significant decline in visual acuity compared to the initial visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Escalate intraocular pressure-lowering therapy by adding a different medication class or recommending selective laser trabeculoplasty","C":"Administer an intravitreal corticosteroid implant to resolve the intraretinal cystic spaces","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1641,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_6220988_2.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. They report a progressive increase in metamorphopsia and a significant decline in visual acuity since their last visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Initiate immediate intravitreal corticosteroid implant therapy for refractory edema","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1642,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_6310682_1.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for a follow-up visit reporting significantly worsening visual acuity and new-onset metamorphopsia. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1643,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_6310682_2.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up, reporting a progressive increase in metamorphopsia and a significant decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Switch to an intravitreal corticosteroid implant therapy or alternative anti-VEGF agent","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1644,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_6310682_3.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up. They now report a significant increase in visual distortion and a noticeable decline in visual acuity compared to their baseline. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Proceed directly to emergency photodynamic therapy (PDT) for the subretinal fluid","D":"Continue observation for another 12 months without any further diagnostic testing"},"answer":"A"},"label":"ERM"}
{"id":1645,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_6391922_1.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for a follow-up visit. The patient reports a progressive worsening of metamorphopsia and a significant decrease in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate prompt anti-VEGF retreatment to evaluate for recurrent macular edema","C":"Proceed with emergency pars plana vitrectomy and internal limiting membrane peeling for a suspected macular hole","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1647,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_6532944_2.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. The patient now describes progressive metamorphopsia and a significant drop in visual acuity since the initial visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1649,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_6993666_1.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up evaluation. The patient describes a progressive worsening of visual distortion and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Escalate therapy by adding another medication class, recommending selective laser trabeculoplasty (SLT), or planning incisional surgery","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1650,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_6993666_2.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for evaluation. During the visit, they describe progressive metamorphopsia and a significant decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1651,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7033723_1.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up with progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1653,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7033723_3.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Over the ensuing months, the patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch immediately to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","D":"Maintain the current exact protocol without any change and discharge the patient"},"answer":"A"},"label":"ERM"}
{"id":1656,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7123170_1.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. Over the past few months, the patient describes progressive metamorphopsia (distortion) and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Consider active intervention such as photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1657,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7123170_2.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for a routine follow-up visit and reports a recent progressive increase in visual distortion and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Maintain the current exact protocol without change, as structural changes are stable"},"answer":"A"},"label":"ERM"}
{"id":1658,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7123170_3.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient describes progressive metamorphopsia (distortion) and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate intravitreal anti-VEGF injections to resolve the macular edema","C":"Proceed with focal laser photocoagulation to seal the leaking vessels","D":"Continue the current observation protocol without further intervention"},"answer":"A"},"label":"ERM"}
{"id":1659,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7123170_4.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up. The patient describes progressive metamorphopsia (distortion) and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1661,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7326803_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up, reporting worsening visual distortion and a significant decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling for a macular hole","D":"Continue observation with routine follow-up and no change in management"},"answer":"A"},"label":"ERM"}
{"id":1662,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7336541_1.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient describes progressive metamorphopsia (distortion) and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1663,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7336541_2.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 6 months later. The patient reports a progressive worsening of metamorphopsia and a significant decline in visual acuity compared to baseline. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate intravitreal anti-VEGF injections or intravitreal corticosteroid implants for macular edema","C":"Perform focal laser photocoagulation to the fovea to address the retinal distortion","D":"Maintain the current observation protocol and continue monitoring without intervention"},"answer":"A"},"label":"ERM"}
{"id":1664,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7596475_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. The patient describes a recent progressive worsening of visual distortion and a significant decline in visual acuity compared to the baseline visit. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management","D":"Continue strict observation for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1665,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7596475_2.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for a follow-up evaluation, describing new and progressive visual distortion (metamorphopsia) along with a marked decline in visual acuity compared to their previous visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate a loading phase of intravitreal anti-VEGF injections followed by a treat-and-extend regimen","C":"Continue strict observation with systemic vascular risk factor management for another 6 months","D":"Perform repeat OCT imaging to evaluate for recurrent macular edema and consider anti-VEGF retreatment"},"answer":"A"},"label":"ERM"}
{"id":1667,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7642868_1.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. The patient describes progressively worsening metamorphopsia and a significant decline in visual acuity since the initial visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate intravitreal injections of an anti-VEGF agent","C":"Perform an urgent sector laser photocoagulation to prevent retinal detachment","D":"Continue observation with periodic OCT imaging and strictly manage systemic blood pressure"},"answer":"A"},"label":"ERM"}
{"id":1668,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7642868_2.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up. Over recent months, they report progressive worsening of visual acuity and increasingly bothersome metamorphopsia. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Proceed directly to photodynamic therapy (PDT) to address persistent subretinal fluid","D":"Continue strict observation with lifestyle modifications for another 12 months without further testing"},"answer":"A"},"label":"ERM"}
{"id":1671,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7815098_2.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 6 months later. The patient reports progressive metamorphopsia and a significant drop in visual acuity compared to the baseline examination. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1672,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7815098_3.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient describes progressive metamorphopsia (distortion) and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1673,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7815098_4.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The patient describes progressive metamorphopsia and a significant drop in visual acuity compared to their previous visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1674,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7901996_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up evaluation. The patient reports a progressive worsening of visual acuity and increasing difficulty with reading, specifically noting new metamorphopsia. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate intravitreal anti-VEGF injections to address retinal fluid accumulation","C":"Administer focal laser photocoagulation to the leaking microaneurysms","D":"Continue observation with serial OCT imaging every 6 months without intervention"},"answer":"A"},"label":"ERM"}
{"id":1675,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7901996_2.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. The patient reports that metamorphopsia has progressively worsened, and visual acuity has significantly decreased. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Continue strict observation with lifestyle modifications for another 12 months without testing","D":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention"},"answer":"A"},"label":"ERM"}
{"id":1677,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_7943951_1.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for a follow-up visit. During the intervening months, they describe the development of progressive metamorphopsia (distortion) and a significant drop in visual acuity compared to their initial presentation. What is the MOST appropriate next step in their management?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue with routine observation for another 12 months without further testing or intervention"},"answer":"A"},"label":"ERM"}
{"id":1679,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_8708516_1.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient describes progressive metamorphopsia (distortion) and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Continue strict observation with lifestyle modifications for another 12 months without testing","D":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present"},"answer":"A"},"label":"ERM"}
{"id":1680,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_8708516_2.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient reports progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1683,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_8851485_1.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up. The patient reports a significant increase in metamorphopsia and a noticeable decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1685,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_8851485_3.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for a routine follow-up visit. They report a significant progression in visual distortion and describe a notable decline in visual acuity compared to previous examinations. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Continue observation to see if the condition spontaneously resolves over the next 6 months","C":"Perform a loading dose of three consecutive anti-VEGF injections followed by a treat-and-extend protocol","D":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention"},"answer":"A"},"label":"ERM"}
{"id":1686,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_8851485_4.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The patient describes progressive metamorphopsia and reports a significant drop in visual acuity since their initial visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Maintain the current exact protocol without change and continue routine observation"},"answer":"A"},"label":"ERM"}
{"id":1687,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_8851485_5.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. The patient describes progressive metamorphopsia (visual distortion) and a significant drop in visual acuity compared to their baseline examination. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1688,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_9092947_1.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient describes progressive metamorphopsia (distortion) and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","D":"Continue observation with strict systemic vascular risk factor management and stroke prevention"},"answer":"A"},"label":"ERM"}
{"id":1691,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_9313328_2.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. During subsequent visits, they describe progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling for a full-thickness defect","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1693,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_9444865_2.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. During subsequent follow-up visits, the patient describes progressive metamorphopsia (distortion) and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Continue strict observation with lifestyle modifications for another 12 months without testing","D":"Extend the anti-VEGF injection interval with continued proactive monitoring"},"answer":"A"},"label":"ERM"}
{"id":1695,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_9444865_4.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up evaluation. The patient describes a progressive worsening of their metamorphopsia and reports a significant drop in visual acuity since the baseline visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling for a macular hole","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"ERM"}
{"id":1696,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_9444865_5.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. The patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1698,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_9444865_7.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for a scheduled follow-up visit. They report a new onset of progressive visual distortion (metamorphopsia) and a significant decline in central visual acuity compared to previous visits. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Initiate a loading dose of intravitreal anti-VEGF injections and extend the interval using a treat-and-extend protocol","D":"Continue strict observation with lifestyle modifications for another 12 months without further testing"},"answer":"A"},"label":"ERM"}
{"id":1699,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_9461085_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. During subsequent follow-up visits, the patient reports progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"ERM"}
{"id":1700,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_9995512_1.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up evaluation. During subsequent visits, the patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Extend the interval for intravitreal anti-VEGF injections using a treat-and-extend protocol","C":"Initiate a secondary loading phase of intravitreal anti-VEGF therapy for recurrent edema","D":"Continue strict observation with lifestyle modifications and routine annual examinations"},"answer":"A"},"label":"ERM"}
{"id":1701,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\ERM\\erm_9995512_2.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. They report a significant increase in visual distortion and a notable drop in visual acuity compared to their baseline visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Prescribe a course of topical and systemic corticosteroids to resolve the acute inflammatory phase","D":"Maintain the current exact protocol without change and discharge the patient"},"answer":"A"},"label":"ERM"}
{"id":1722,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\RAO\\rao_7825274_4.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation several weeks later. Follow-up imaging reveals that the acute retinal edema has largely resolved, now showing significant thinning and atrophy of the inner retinal layers. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Escalate therapy by adding another medication class or recommending selective laser trabeculoplasty (SLT)","D":"Continue observation with no further systemic workup as the retinal findings have self-resolved"},"answer":"A"},"label":"RAO"}
{"id":1724,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\RAO\\rao_8792811_1.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for evaluation several weeks later. Follow-up imaging shows that the acute inner retinal edema has fully resolved, but the inner retinal layers now appear noticeably thinned and atrophic compared to the initial scan. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"RAO"}
{"id":1727,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\RVO\\rvo_1770807_1.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 6 months later. Following successful resolution of their macular edema, they return with a sudden new onset of blurred vision. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","B":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"RVO"}
{"id":1729,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\RVO\\rvo_1770807_3.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Following successful resolution of macular edema, the patient returns months later complaining of a sudden new onset of blurred vision. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","D":"Continue with routine annual comprehensive eye examinations and standard wellness monitoring"},"answer":"A"},"label":"RVO"}
{"id":1735,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\RVO\\rvo_2355184_2.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up several months after successful resolution of macular edema. They now complain of a sudden new onset of blurred vision in the affected eye. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy due to suspected treatment resistance","C":"Recommend immediate surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Continue with routine annual comprehensive eye examinations and standard wellness monitoring"},"answer":"A"},"label":"RVO"}
{"id":1750,"image_path":"E:\\OCT\\OCT-Bench\\OCTDL\\RVO\\rvo_3521165_2.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for evaluation months later. Follow-up imaging reveals successful resolution of the macular edema, but the patient now reports a sudden new onset of blurred vision. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","B":"Schedule an urgent pars plana vitrectomy with epiretinal membrane peeling to relieve traction","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","D":"Continue strict observation with routine visual field testing annually"},"answer":"A"},"label":"RVO"}
{"id":1833,"image_path":"E:\\OCT\\OCT-Bench\\GOALS\\Glaucoma\\0008.png","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for their scheduled follow-up. Although they have maintained strict adherence to their current topical medication regimen, sequential structural testing over the past six months reveals confirmed progression of retinal nerve fiber layer thinning and visual field loss. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Escalate therapy by adding another medication class, recommending selective laser trabeculoplasty (SLT), or planning incisional surgery","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Continue the current intraocular pressure-lowering drops and discharge the patient for routine annual care"},"answer":"A"},"label":"Glaucoma"}
{"id":1841,"image_path":"E:\\OCT\\OCT-Bench\\GOALS\\Glaucoma\\0022.png","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up. Despite maintaining the current intraocular pressure-lowering eye drops, sequential testing shows confirmed structural progression of retinal nerve fiber layer loss. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Escalate therapy by adding another medication class, recommending selective laser trabeculoplasty, or planning incisional surgery","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"Glaucoma"}
{"id":1848,"image_path":"E:\\OCT\\OCT-Bench\\GOALS\\Glaucoma\\0042.png","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for routine follow-up. Despite consistently adhering to their current topical therapy regimen, recent structural imaging and visual field testing reveal confirmed progressive thinning of the retinal nerve fiber layer (RNFL) and localized visual field loss. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Escalate therapy by adding another medication class, recommending selective laser trabeculoplasty (SLT), or planning incisional surgery","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Continue the current exact medication protocol without change and schedule a routine 12-month follow-up"},"answer":"A"},"label":"Glaucoma"}
{"id":1852,"image_path":"E:\\OCT\\OCT-Bench\\GOALS\\Glaucoma\\0057.png","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up evaluation. Despite maintaining the current intraocular pressure-lowering eye drops, sequential testing over the past year confirms progressive structural thinning of the retinal nerve fiber layer without significant intraocular pressure elevation. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Escalate therapy by adding another medication class, recommending selective laser trabeculoplasty (SLT), or planning incisional surgery","B":"Switch to an intravitreal corticosteroid implant or alternative anti-VEGF agent to address the refractory edema","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling to address progressive metamorphopsia","D":"Maintain the current exact protocol without any changes, as intraocular pressure remains within normal limits"},"answer":"A"},"label":"Glaucoma"}
{"id":1870,"image_path":"E:\\OCT\\OCT-Bench\\GOALS\\Glaucoma\\0095.png","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. Despite maintaining their current topical therapy regimen over the past year, sequential structural testing reveals confirmed progression of retinal nerve fiber layer loss and worsening visual field defects. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Escalate therapy by adding another medication class, recommending selective laser trabeculoplasty (SLT), or planning incisional surgery","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"Glaucoma"}
{"id":1877,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-174290_16.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The subretinal fluid persists or worsens after 3 months of conservative observation, with declining visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"Normal"}
{"id":1881,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-176224_15.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"Normal"}
{"id":1895,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-180995_15.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for routine evaluation. During subsequent visits over the following months, the patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue with routine annual comprehensive eye examinations without intervention"},"answer":"A"},"label":"Normal"}
{"id":1896,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-181061_15.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"Normal"}
{"id":1902,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-183884_14.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for evaluation after 3 months of initial observation. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"Normal"}
{"id":1909,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-184958_16.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for a follow-up evaluation 3 months later. The patient reports a progressive worsening of metamorphopsia and a significant decline in visual acuity since the last visit. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"Normal"}
{"id":1924,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-198794_16.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. During subsequent follow-up visits, the patient reports progressive metamorphopsia and a significant decline in visual acuity. What is the MOST appropriate next step in their management?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue routine annual comprehensive eye examinations and standard wellness monitoring"},"answer":"A"},"label":"Normal"}
{"id":1935,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-199974_15.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"Normal"}
{"id":1938,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-200110_16.jpg","vqa":{"question":"A patient presenting with the condition demonstrated in this OCT image returns for evaluation. After multiple consecutive treatments, follow-up imaging reveals that the intraretinal cystic spaces and macular thickening remain refractory with no significant improvement. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue the current exact protocol without change for another 6 months"},"answer":"A"},"label":"Normal"}
{"id":1942,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-201396_15.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. The patient reports a progressive decline in visual acuity and worsening metamorphopsia. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"Normal"}
{"id":1946,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-201553_15.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up. The patient remains completely asymptomatic with no new visual complaints during subsequent annual evaluations. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Continue with routine annual comprehensive eye examinations and standard wellness monitoring","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy"},"answer":"A"},"label":"Normal"}
{"id":1964,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-210758_15.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"Normal"}
{"id":1976,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-214584_17.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Extend the anti-VEGF injection interval and continue proactive monitoring using a Treat-and-Extend approach","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"Normal"}
{"id":1992,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-58392_15.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. During subsequent follow-up visits, the patient reports progressive visual distortion and a significant decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue with routine annual comprehensive eye examinations and standard wellness monitoring"},"answer":"A"},"label":"Normal"}
{"id":2003,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-67030_16.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up evaluation. Upon review, the imaging demonstrates complete resolution of subretinal fluid with restoration of a normal foveal contour, and the patient reports significant improvement in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Continue with routine annual comprehensive eye examinations and standard wellness monitoring","B":"Extend the anti-VEGF injection interval with continued proactive monitoring (Treat-and-Extend)","C":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Escalate therapy by adding another medication class or recommending selective laser trabeculoplasty (SLT)"},"answer":"A"},"label":"Normal"}
{"id":2023,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-75162_15.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. The patient reports a progressive worsening of visual acuity and increased distortion, with subsequent imaging confirming the progression of their initial presentation. What is the MOST appropriate next step in their management?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate treatment with intravitreal anti-VEGF injections for macular edema","C":"Commence intravitreal corticosteroid implant therapy for refractory fluid","D":"Continue current conservative observation with annual comprehensive eye examinations"},"answer":"A"},"label":"Normal"}
{"id":2028,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-91588_33.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The patient remains completely asymptomatic with no new visual complaints during subsequent annual evaluations. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Continue with routine annual comprehensive eye examinations and standard wellness monitoring","B":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Escalate therapy by adding another medication class, recommending selective laser trabeculoplasty (SLT), or planning incisional surgery"},"answer":"A"},"label":"Normal"}
{"id":2046,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-94895_15.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. The patient describes a progressive increase in visual distortion and a notable decline in visual acuity since the baseline examination. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications without any diagnostic testing or intervention"},"answer":"A"},"label":"Normal"}
{"id":2049,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-95131_18.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. During subsequent follow-up visits, the patient describes progressive metamorphopsia (distortion) and a significant drop in visual acuity, with corresponding interval changes on imaging. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Proceed directly to emergency pars plana vitrectomy with gas tamponade","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"Normal"}
{"id":2053,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-96717_15.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up 6 months later. The patient reports a progressive increase in metamorphopsia and a significant decline in visual acuity, and repeat OCT confirms structural worsening. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate photodynamic therapy (PDT) or focal laser photocoagulation","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 6 months without testing"},"answer":"A"},"label":"Normal"}
{"id":2055,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-96869_15.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The patient describes progressive metamorphopsia and a significant drop in visual acuity during subsequent visits. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"Normal"}
{"id":2071,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\Normal\\o-h-99524_23.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up evaluation. Over the subsequent months, the patient describes progressive metamorphopsia (distortion) and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","D":"Continue with routine annual comprehensive eye examinations and standard wellness monitoring"},"answer":"A"},"label":"Normal"}
{"id":2080,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-28254-l_001.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up. During subsequent visits, the patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"dryAMD"}
{"id":2086,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-43297643-l_001.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up evaluation. Follow-up imaging reveals that the drusenoid pigment epithelial detachments have increased in size and the patient now reports a subtle blurring of central vision. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Initiate prophylactic anti-VEGF therapy to reduce the risk of progression to neovascularization","B":"Perform pars plana vitrectomy with epiretinal membrane peeling to relieve retinal traction","C":"Continue strict observation with routine annual comprehensive eye exams and standard wellness monitoring","D":"Escalate therapy by adding another medication class or planning incisional glaucoma surgery"},"answer":"A"},"label":"dryAMD"}
{"id":2087,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-43537087-r_000.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for evaluation. Follow-up imaging reveals that the subretinal fluid has persisted without spontaneous resolution after 3 months of observation, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Proceed with pars plana vitrectomy with internal limiting membrane peeling to close the defect","C":"Initiate a loading phase of intravitreal anti-VEGF injections","D":"Continue strict observation for another 6 months without further testing"},"answer":"A"},"label":"dryAMD"}
{"id":2091,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-43826947-l_000.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation several months later. The patient reports a gradual progression of metamorphopsia and a significant decline in best-corrected visual acuity. What is the MOST appropriate next step in their management?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"dryAMD"}
{"id":2092,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-43826947-l_001.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. The patient reports worsening metamorphopsia and a recent decline in visual acuity compared to their previous visit. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate intravitreal anti-VEGF injections for macular edema","C":"Prescribe conservative observation with a strict regimen of anti-oxidant supplements","D":"Perform immediate laser photocoagulation for subfoveal neovascularization"},"answer":"A"},"label":"dryAMD"}
{"id":2093,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-43826947-l_002.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for a follow-up visit. They report progressive worsening of their central vision and increasing metamorphopsia over the past 6 months. What is the MOST appropriate next step in their management?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate a loading phase of intravitreal anti-VEGF injections","C":"Perform focal laser photocoagulation to the edges of the membrane","D":"Continue observation and schedule a routine comprehensive eye exam in 12 months"},"answer":"A"},"label":"dryAMD"}
{"id":2098,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-43895994_001.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. The patient reports progressively worsening metamorphopsia and a significant drop in visual acuity compared to the initial visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"dryAMD"}
{"id":2105,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-4073-l_000.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up evaluation. Over the next few months, the patient reports a significant decline in visual acuity and increased distortion of straight lines. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Escalate therapy by adding another IOP-lowering medication class or performing selective laser trabeculoplasty","D":"Continue strict observation with routine annual comprehensive eye examinations for another 12 months without testing"},"answer":"A"},"label":"dryAMD"}
{"id":2106,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-4073-l_001.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for a follow-up visit. Over the subsequent months, they describe a progressive worsening of metamorphopsia and a significant decline in visual acuity, despite the condition initially appearing stable. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Escalate therapy by adding another medication class or recommending selective laser trabeculoplasty","C":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"dryAMD"}
{"id":2113,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-4695-l.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up, reporting progressive metamorphopsia and a significant drop in visual acuity since their last visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"dryAMD"}
{"id":2116,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-4742-r_000.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 12 months later. The patient reports that their best-corrected visual acuity has progressively worsened, and they now experience significant central visual distortion that interferes with reading. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Administer an intravitreal anti-VEGF injection to address the suspected neovascularization","C":"Initiate treatment with intraocular pressure-lowering drops to prevent further optic nerve damage","D":"Advise the patient that the condition is stable and schedule a routine follow-up in 24 months"},"answer":"A"},"label":"dryAMD"}
{"id":2118,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-4753-l_000.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The patient reports progressive metamorphopsia and a significant decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Escalate therapy by adding another intraocular pressure-lowering medication class or recommending selective laser trabeculoplasty","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"dryAMD"}
{"id":2119,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-4753-l_001.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. The patient describes a progressive increase in metamorphopsia and a significant decline in visual acuity since their last visit. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Maintain the current exact protocol without change and continue observation for another 12 months"},"answer":"A"},"label":"dryAMD"}
{"id":2121,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-4894-l.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. After several months of observation, the patient reports worsening central vision and new metamorphopsia. What is the MOST appropriate next step in their management?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","C":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue with routine annual comprehensive eye examinations and standard wellness monitoring"},"answer":"A"},"label":"dryAMD"}
{"id":2122,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-4906-r.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up evaluation. The patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"dryAMD"}
{"id":2128,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5142-r_001.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for a routine follow-up evaluation. Follow-up imaging reveals that the subretinal fluid has completely resolved and visual acuity has stabilized following initial conservative management. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Continue routine annual comprehensive eye examinations and standard wellness monitoring","B":"Extend the anti-VEGF injection interval with continued proactive monitoring using a treat-and-extend protocol","C":"Escalate therapy by adding another intraocular pressure-lowering medication class or recommending selective laser trabeculoplasty","D":"Recommend immediate surgical intervention with pars plana vitrectomy and epiretinal membrane peeling"},"answer":"A"},"label":"dryAMD"}
{"id":2130,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5143-r_001.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up evaluation. The patient reports a gradual onset of new visual symptoms, specifically progressive metamorphopsia (distortion) and a decline in visual acuity over the past few months. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate intravitreal anti-VEGF injections to address the structural changes","C":"Prescribe a short course of high-dose oral corticosteroids to reduce the traction","D":"Maintain the current observation protocol and re-evaluate the patient in 12 months"},"answer":"A"},"label":"dryAMD"}
{"id":2134,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5154-l_001.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Follow-up imaging reveals that the subretinal fluid persists and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Initiate treatment with intravitreal anti-VEGF injections to address choroidal neovascularization","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"dryAMD"}
{"id":2136,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5174-l.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up. Imaging and clinical testing now show progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"dryAMD"}
{"id":2137,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5188-r_000.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up evaluation. The imaging reveals progressive metamorphopsia and a significant decline in visual acuity since the initial visit. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"dryAMD"}
{"id":2140,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5292-l.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. Despite maintaining the current topical therapeutic regimen, sequential follow-up imaging shows confirmed structural progression of the nerve fiber layer. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Escalate therapy by adding another medication class, recommending selective laser trabeculoplasty (SLT), or planning incisional surgery","B":"Initiate prompt intravitreal anti-VEGF injections to resolve the intraretinal cystic spaces","C":"Recommend immediate pars plana vitrectomy with epiretinal membrane peeling","D":"Continue the current medication regimen and schedule the next routine evaluation in 12 months"},"answer":"A"},"label":"dryAMD"}
{"id":2141,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5354-r.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for a follow-up visit. The patient reports progressive metamorphopsia and a significant decline in visual acuity compared to previous visits. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Continue strict observation with lifestyle modifications for another 12 months without testing","D":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment"},"answer":"A"},"label":"dryAMD"}
{"id":2142,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5428-r.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. The patient describes a progressive increase in metamorphopsia and a noticeable decline in visual acuity since the initial visit. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Extend the anti-VEGF injection interval with continued proactive monitoring (Treat-and-Extend)","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"dryAMD"}
{"id":2146,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5579-l.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. The patient describes a progressive worsening of their metamorphopsia and a significant decline in best-corrected visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"dryAMD"}
{"id":2147,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5579-r_000.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. Over the past 6 months, the patient reports progressive worsening of central vision and increasing metamorphopsia, which is now significantly impacting daily activities like reading. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate a loading phase of intravitreal anti-VEGF injections for wet AMD","C":"Schedule immediate photodynamic therapy (PDT) for central serous chorioretinopathy","D":"Continue conservative observation with lifestyle modifications for another 6 months"},"answer":"A"},"label":"dryAMD"}
{"id":2154,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5706-l_001.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. The patient reports a progressive worsening of central vision and a subjective increase in metamorphopsia. The longitudinal clinical course is most consistent with which adjustment in management?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate intravitreal anti-VEGF injections to reduce macular edema","C":"Continue strict observation with lifestyle modifications for another 12 months without testing","D":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention"},"answer":"A"},"label":"dryAMD"}
{"id":2157,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5760-r_000.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. They have recently noticed a significant worsening of their central vision and increased visual distortion compared to their last visit. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Escalate therapy by adding another medication class or recommending selective laser trabeculoplasty","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"dryAMD"}
{"id":2159,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5770-l_000.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up after six months of observation. The patient reports no change in their symptoms, and repeat imaging confirms that the retinal structure remains stable with no signs of disease progression. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Continue with routine annual comprehensive eye examinations and standard wellness monitoring","B":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Extend the anti-VEGF injection interval with continued proactive monitoring using a treat-and-extend protocol"},"answer":"A"},"label":"dryAMD"}
{"id":2160,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5770-l_001.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. At the 1-year follow-up visit, they describe a noticeable worsening of metamorphopsia and a significant decline in visual acuity compared to their baseline exam. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate anti-VEGF therapy to prevent neovascularization and reduce macular edema","C":"Proceed with photodynamic therapy to address persistent subretinal fluid","D":"Discharge the patient as the condition remains stable and observation is sufficient"},"answer":"A"},"label":"dryAMD"}
{"id":2161,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5770-l_002.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for evaluation. Follow-up imaging reveals progressive metamorphopsia and a significant decline in visual acuity due to increasing macular thickening. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Initiate treatment with an intravitreal corticosteroid implant or switch to an alternative anti-VEGF agent","D":"Continue strict observation with lifestyle modifications and routine monitoring"},"answer":"A"},"label":"dryAMD"}
{"id":2165,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5791-l_000.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up 12 months later. They remain completely asymptomatic with no new visual complaints, and the retinal architecture remains stable. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Continue with routine annual comprehensive eye examinations and standard wellness monitoring","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Extend the anti-VEGF injection interval with continued proactive monitoring"},"answer":"A"},"label":"dryAMD"}
{"id":2166,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5791-l_001.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation after 3 months of regular follow-up. The structural findings and visual acuity remain completely unchanged from the baseline examination. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Continue with routine annual comprehensive eye examinations and standard wellness monitoring","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Escalate therapy by adding another medication class or recommending selective laser trabeculoplasty"},"answer":"A"},"label":"dryAMD"}
{"id":2167,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5791-l_002.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for routine evaluation 12 months later. The new imaging reveals that the condition has progressed to include the development of subretinal fluid and increased choroidal neovascularization, and the patient reports a sudden decrease in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Initiate intravitreal anti-VEGF injection therapy","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform surgical intervention with pars plana vitrectomy and membrane peeling","D":"Continue the current observation protocol with annual follow-up"},"answer":"A"},"label":"dryAMD"}
{"id":2168,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5791-r_000.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for a scheduled follow-up visit. The patient reports a progressive increase in metamorphopsia and a significant drop in visual acuity since the initial presentation. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate a loading phase of intravitreal anti-VEGF injections followed by a treat-and-extend regimen","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","D":"Continue strict observation with lifestyle modifications for another 12 months without structural testing"},"answer":"A"},"label":"dryAMD"}
{"id":2170,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5801-l.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The patient describes progressive metamorphopsia and a significant drop in visual acuity since the initial visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Extend the anti-VEGF injection interval with continued proactive monitoring","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"dryAMD"}
{"id":2171,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5804_000.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for evaluation. Subsequent follow-up visits reveal that the patient describes progressive metamorphopsia (distortion) and a significant drop in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Continue strict observation with lifestyle modifications for another 12 months without testing","C":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","D":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling"},"answer":"A"},"label":"dryAMD"}
{"id":2174,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\dryAMD\\o-d-ICG-5804_003.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up. They report a gradual worsening of metamorphopsia and a significant decrease in visual acuity over the past 6 months. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Escalate therapy by adding another medication class or recommending selective laser trabeculoplasty","C":"Initiate prompt anti-VEGF retreatment to resolve recurrent macular edema","D":"Continue routine annual comprehensive eye examinations and standard wellness monitoring"},"answer":"A"},"label":"dryAMD"}
{"id":2186,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-18056160_001.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The subretinal fluid has persisted without any spontaneous resolution after 3 months of conservative observation, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2197,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-43233942-l_001.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image presents for a follow-up visit. The patient reports a progressive increase in metamorphopsia and a noticeable decline in visual acuity compared to previous visits. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Extend the interval of current intravitreal anti-VEGF injections with continued proactive monitoring","C":"Initiate prompt anti-VEGF retreatment to evaluate for and resolve recurrent macular edema","D":"Continue strict observation with lifestyle modifications and routine annual comprehensive eye examinations"},"answer":"A"},"label":"PCV"}
{"id":2199,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-43341420_000.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2208,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-43669339_000.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for a 3-month follow-up evaluation. The patient reports persistent blurred vision, and repeat imaging reveals that the subfoveal fluid has not resolved and has slightly increased in height. What is the MOST appropriate next step in their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue the current conservative observation protocol with lifestyle modifications for another 12 months"},"answer":"A"},"label":"PCV"}
{"id":2210,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-43690083.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. Follow-up imaging reveals that the intraretinal cystic spaces and macular thickening remain refractory to treatment despite multiple consecutive anti-VEGF injections. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2213,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-43769735_002.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Imaging reveals persistent subretinal fluid and choroidal hyperpermeability after a course of anti-VEGF injections, with no improvement in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to photodynamic therapy (PDT) or focal laser photocoagulation","B":"Initiate treatment with an intravitreal corticosteroid implant or an alternative anti-VEGF agent","C":"Recommend urgent pars plana vitrectomy with internal limiting membrane peeling","D":"Continue the current anti-VEGF injection protocol for another 3 months without change"},"answer":"A"},"label":"PCV"}
{"id":2216,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-43936099_000.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up. After multiple consecutive anti-VEGF injections, follow-up imaging reveals that the intraretinal fluid and subretinal fluid have completely resolved, and the patient reports a significant improvement and stabilization in their visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring (Treat-and-Extend)","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2219,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-43984008_000.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up evaluation. The imaging reveals that despite initial management, the subretinal fluid and pigment epithelial detachment remain persistent, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Initiate anti-VEGF intravitreal injections targeting the underlying neovascularization","B":"Perform immediate pars plana vitrectomy with internal limiting membrane peeling","C":"Continue strict observation with lifestyle modifications for another 12 months","D":"Escalate therapy by adding a topical carbonic anhydrase inhibitor and initiating selective laser trabeculoplasty"},"answer":"A"},"label":"PCV"}
{"id":2221,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-44030531_000.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image presents for follow-up evaluation. They report experiencing progressive metamorphopsia and a significant decline in visual acuity since the initial visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate intravitreal anti-VEGF injections to resolve the macular edema","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"PCV"}
{"id":2222,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-44030531_001.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up. Following an initial intravitreal anti-VEGF injection, the patient exhibits worsening symptoms and repeat imaging shows no reduction in the subretinal fluid and new areas of intraretinal hemorrhage. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2225,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-44296721.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. Follow-up imaging reveals that the subretinal fluid has persisted and worsened over the past 3 months despite conservative observation, with a concurrent decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Initiate monthly intravitreal anti-VEGF injections and reassess after a 3-month loading phase","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2232,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-44465469-r.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. After receiving initial intravitreal anti-VEGF injections, the subretinal and intraretinal fluid have completely resolved and the patient reports stable visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt retreatment","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2236,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-3762-r_001.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2250,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4109-l.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. The patient reports a progressive increase in visual distortion and a significant decrease in visual acuity compared to their baseline examination. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2251,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4109-r.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The subretinal fluid persists and the patient reports a progressive decline in visual acuity after a period of observation. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Recommend surgical intervention with pars plana vitrectomy and membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2269,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4235-r_001.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. After a period of close monitoring without active intervention, the patient reports a progressive decline in visual acuity and worsening metamorphopsia. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Initiate treatment with intravitreal anti-VEGF injections or corticosteroid implants","D":"Continue observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2278,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4281-r.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Follow-up imaging reveals that the intraretinal cystic spaces and macular thickening remain refractory or worsen despite multiple consecutive anti-VEGF injections. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Recommend immediate surgical intervention with pars plana vitrectomy and membrane peeling","D":"Maintain the exact current injection protocol without any changes"},"answer":"A"},"label":"PCV"}
{"id":2284,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4294-r.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up. The subretinal fluid persists and visual acuity continues to decline after an initial period of observation. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Initiate intravitreal anti-VEGF injections using a treat-and-extend protocol","C":"Perform emergency pars plana vitrectomy to relieve the traction","D":"Maintain strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2291,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4339-r_000.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up 3 months later. The imaging shows that the subretinal fluid has persisted or worsened, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Extend the current observation period for another 6 months without testing","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy"},"answer":"A"},"label":"PCV"}
{"id":2296,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4374-l_000.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2299,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4374-r_001.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up after multiple consecutive anti-VEGF injections. Subsequent imaging reveals that the subretinal hemorrhage and fluid have shown a complete resolution, and the patient\u0027s visual acuity has stabilized. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring (Treat-and-Extend)","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","D":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention"},"answer":"A"},"label":"PCV"}
{"id":2309,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4469-l_000.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. After initiating anti-VEGF therapy, the subretinal fluid shows incomplete resolution and the polypoidal lesions remain active on imaging. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Administer a combination of anti-VEGF therapy and photodynamic therapy (PDT)","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Maintain the current monthly anti-VEGF injection schedule without changes","D":"Refer the patient for immediate pars plana vitrectomy and epiretinal membrane peeling"},"answer":"A"},"label":"PCV"}
{"id":2315,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4538-l_000.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up. The patient reports a progressive worsening of their visual symptoms, including increased metamorphopsia. A new OCT scan reveals a marked increase in the retinal thickness and a more pronounced distortion of the foveal contour. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Initiate systemic vascular risk factor management and strict stroke prevention measures","D":"Continue strict observation with lifestyle modifications without further intervention"},"answer":"A"},"label":"PCV"}
{"id":2318,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4558-l_001.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up after an initial course of anti-VEGF therapy. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2338,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4651-l_000.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The patient reports a persistent decline in visual acuity and increasing metamorphopsia, with structural findings of a fully restored foveal contour following recent surgical intervention. What is the MOST appropriate next step in their management strategy?","options":{"A":"Maintain regular outpatient follow-up to monitor visual recovery and structural stabilization","B":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","C":"Initiate prompt anti-VEGF retreatment to address residual macular edema","D":"Escalate therapy by adding another medication class to manage intraocular pressure"},"answer":"A"},"label":"PCV"}
{"id":2347,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4671-r.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image is re-evaluated 6 months after initial observation. The subretinal fluid has persisted and worsened, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2362,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4715-r_001.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up evaluation. The follow-up imaging reveals that despite initial conservative management, the subretinal fluid has persisted and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2368,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4740-l_002.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for evaluation. Follow-up imaging reveals that the subretinal pigment epithelial fluid and exudation have completely resolved, and their visual acuity has stabilized. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Extend the anti-VEGF injection interval with continued proactive monitoring (Treat-and-Extend)","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","D":"Maintain regular outpatient follow-up to monitor visual recovery and structural stabilization without intervention"},"answer":"A"},"label":"PCV"}
{"id":2379,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4772-r_002.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up evaluation. After undergoing initial anti-VEGF therapy, the follow-up imaging reveals persistent subretinal fluid and choroidal hyperpermeability despite multiple treatments, and the patient continues to experience visual symptoms. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Escalate therapy by adding another medication class, recommending selective laser trabeculoplasty (SLT), or planning incisional surgery","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2383,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4775-l_002.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image presents for a follow-up evaluation 3 months after initiating treatment. Follow-up imaging reveals that the intraretinal cystic spaces and macular thickening remain refractory, showing no significant structural improvement despite consecutive monthly anti-VEGF injections. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the anti-VEGF injection interval and continue proactive monitoring with a treat-and-extend regimen","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","D":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling"},"answer":"A"},"label":"PCV"}
{"id":2397,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4819-r_001.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2400,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4845-l_000.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. Despite initial conservative observation, the condition has progressed with worsening subretinal fluid accumulation and a significant decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2402,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4847-l_000.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Despite maintaining strict intraocular pressure control with current medications, sequential imaging reveals progressive deepening of the macular cup-to-disc ratio and worsening of the retinal nerve fiber layer. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Escalate therapy by adding another medication class, recommending selective laser trabeculoplasty (SLT), or planning incisional surgery","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Initiate active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2407,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4878-r_001.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for a follow-up visit. The patient reports a progressive worsening of metamorphopsia and a significant drop in visual acuity compared to the initial visit. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2410,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4893-r_001.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image presents for follow-up 6 months later. They are currently symptomatic and, despite multiple previous focal treatments, the subretinal fluid persists and visual acuity has declined. What is the MOST appropriate next step in the management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2411,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4895-l.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up evaluation. The patient reports a progressive worsening of visual distortion and a significant decline in visual acuity since the initial visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2419,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-4952-l.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up after initial conservative observation. Follow-up imaging reveals that the subretinal fluid has persisted and even worsened, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2429,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5040-r_002.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 6 months later. Follow-up imaging reveals that the subretinal fluid and pigment epithelial detachment have persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2434,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5094-r_001.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image is observed over several months. During subsequent follow-up visits, the patient describes progressive metamorphopsia and a significant drop in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Extend the anti-VEGF injection interval with continued proactive monitoring (Treat-and-Extend)","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2437,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5110-l_001.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image presents for a follow-up visit after an initial treatment period. Clinical examination and imaging reveal that the condition has stabilized with structural improvement, and visual acuity has been maintained. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Maintain regular outpatient follow-up to monitor visual recovery and structural stabilization","B":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Extend the anti-VEGF injection interval with continued proactive monitoring"},"answer":"A"},"label":"PCV"}
{"id":2438,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5122-r_000.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Follow-up imaging reveals that the intraretinal cystic spaces and macular thickening remain refractory and are worsening despite multiple consecutive anti-VEGF injections. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Continue the current exact protocol without any changes"},"answer":"A"},"label":"PCV"}
{"id":2439,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5122-r_001.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for evaluation. Follow-up imaging reveals that the subfoveal hemorrhage and associated fluid have persisted without resolution, and the patient reports a further decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Perform photodynamic therapy (PDT) combined with anti-VEGF injections","B":"Continue strict observation with lifestyle modifications and delay treatment","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy"},"answer":"A"},"label":"PCV"}
{"id":2467,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5199-r_000.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform immediate pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2474,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5227-l.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. The patient describes a progressive increase in metamorphopsia and a significant decrease in visual acuity since the initial presentation. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2496,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5374-r_001.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for evaluation following a 3-month course of conservative observation. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2500,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5401_001.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the intraretinal cystic spaces and macular thickening remain refractory and worsened despite multiple consecutive anti-VEGF injections. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the current anti-VEGF injection interval and continue proactive monitoring","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Maintain the current exact protocol without change and discharge the patient"},"answer":"A"},"label":"PCV"}
{"id":2505,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5433-r_000.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. The subretinal fluid persists or worsens after 3 months of conservative observation, with declining visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2517,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5458-r_000.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for a follow-up visit. Over the past year, despite initial management, the patient reports progressively worsening metamorphopsia and a significant decline in visual acuity. Subsequent OCT imaging confirms the structural findings have persisted or worsened. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Escalate medical therapy by adding an alternative anti-VEGF agent or corticosteroid implant","C":"Perform photodynamic therapy (PDT) or focal laser photocoagulation","D":"Continue strict observation with lifestyle modifications for another 6 months without further testing"},"answer":"A"},"label":"PCV"}
{"id":2526,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5525_000.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The patient reports that the metamorphopsia has worsened and visual acuity has significantly declined. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"PCV"}
{"id":2528,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5525_002.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image is re-evaluated after a 3-month course of conservative observation. Follow-up imaging reveals persistent subretinal fluid and declining visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2530,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5590_001.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. Despite completing a standard loading phase of anti-VEGF injections, the intraretinal cystic spaces and macular thickening persist, showing no improvement in structural or visual parameters. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","B":"Extend the anti-VEGF injection interval with continued proactive monitoring using a treat-and-extend protocol","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Discontinue all active treatments and revert to long-term observation due to treatment resistance"},"answer":"A"},"label":"PCV"}
{"id":2534,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5606-r_000.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image is evaluated after 6 months of observation. The patient reports a significant decline in visual acuity and new-onset metamorphopsia, despite the structural findings remaining relatively stable. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2538,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5665_001.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The subretinal fluid has persisted and even increased after three months of close observation, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next step in their management?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Maintain regular outpatient follow-up to monitor visual recovery and structural stabilization","D":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention"},"answer":"A"},"label":"PCV"}
{"id":2541,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5674-l_002.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2544,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5684_000.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. The subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2545,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5684_001.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for a follow-up visit. The patient describes a progressive worsening of metamorphopsia and a significant drop in visual acuity compared to baseline. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Escalate therapy by adding another intraocular pressure-lowering medication class","D":"Continue strict observation with lifestyle modifications for another 12 months without structural testing"},"answer":"A"},"label":"PCV"}
{"id":2551,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5752-r_002.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"PCV"}
{"id":2552,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\PCV\\o-p-ICG-5757_000.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up. The patient reports progressive metamorphopsia and a significant decline in best-corrected visual acuity compared to their previous visit. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","B":"Initiate rescue therapy with an intravitreal anti-VEGF injection","C":"Proceed immediately to photodynamic therapy (PDT) for the subfoveal lesion","D":"Continue strict observation with lifestyle modifications for another 6 months"},"answer":"A"},"label":"PCV"}
{"id":2598,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-43330743_001.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for a scheduled follow-up after receiving an initial loading phase of intravitreal anti-VEGF injections. Imaging now shows complete resolution of the intraretinal and subretinal fluid, and the patient reports stable, improved visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring (Treat-and-Extend)","B":"Continue strict observation with lifestyle modifications for another 12 months without testing","C":"Recommend surgical intervention with pars plana vitrectomy and membrane peeling","D":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present"},"answer":"A"},"label":"wetAMD"}
{"id":2599,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-43330743_002.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up after a series of initial treatments. Imaging now reveals complete resolution of the intraretinal and subretinal fluid, and the patient reports stable, improved visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring","B":"Proceed to emergency pars plana vitrectomy with internal limiting membrane peeling","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","D":"Maintain the current exact monthly injection protocol indefinitely without any changes"},"answer":"A"},"label":"wetAMD"}
{"id":2627,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-43682399_000.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. After initial loading injections, the imaging reveals complete resolution of the intraretinal/subretinal fluid and the patient\u0027s visual acuity has stabilized. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","D":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling"},"answer":"A"},"label":"wetAMD"}
{"id":2675,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-3943-l.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up after a series of initial anti-VEGF loading injections. The imaging now shows complete resolution of the intraretinal and subretinal fluid with stable visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring (Treat-and-Extend)","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"wetAMD"}
{"id":2679,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-4004-l.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up after a series of initial anti-VEGF loading injections. Follow-up imaging reveals a complete resolution of the intraretinal and subretinal fluid with stabilized visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring (Treat-and-Extend)","B":"Perform a repeat OCT to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Maintain the current monthly injection frequency indefinitely without reassessment"},"answer":"A"},"label":"wetAMD"}
{"id":2706,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-4126-l.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Despite maintaining intraocular pressure-lowering eye drops, sequential testing shows confirmed structural progression of the nerve fiber layer. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Escalate therapy by adding another medication class, recommending selective laser trabeculoplasty (SLT), or planning incisional surgery","B":"Extend the anti-VEGF injection interval with continued proactive monitoring (Treat-and-Extend)","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"wetAMD"}
{"id":2773,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-4528-r.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Following a successful course of initial loading injections, the patient now demonstrates complete resolution of intraretinal and subretinal fluid with stable visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue the current fixed monthly injection protocol indefinitely without reassessment"},"answer":"A"},"label":"wetAMD"}
{"id":2779,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-4545-l.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up. Follow-up imaging reveals complete resolution of intraretinal and subretinal fluid with stable visual acuity following the initial loading injections. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring (Treat-and-Extend)","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Maintain the current exact injection protocol indefinitely without any changes"},"answer":"A"},"label":"wetAMD"}
{"id":2781,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-4547-l.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up. The patient has undergone a series of intravitreal injections, and the follow-up OCT reveals a complete resolution of the intraretinal and subretinal fluid with a stable visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the injection interval with continued proactive monitoring using a treat-and-extend protocol","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Maintain the current exact monthly injection protocol indefinitely without re-evaluation"},"answer":"A"},"label":"wetAMD"}
{"id":2817,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-4662-l_000.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation. Following a course of initial anti-VEGF loading injections, follow-up imaging reveals complete resolution of intraretinal and subretinal fluid with stable visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring (Treat-and-Extend)","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","D":"Recommend immediate surgical intervention with pars plana vitrectomy and epiretinal membrane peeling"},"answer":"A"},"label":"wetAMD"}
{"id":2830,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-4724-l_000.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for evaluation after completing an initial loading phase of intravitreal anti-VEGF therapy. The follow-up OCT shows complete resolution of intraretinal and subretinal fluid, and the patient reports stable visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring (Treat-and-Extend)","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","D":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention"},"answer":"A"},"label":"wetAMD"}
{"id":2857,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-4805-r_000.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up after initiating anti-VEGF therapy. Evaluation shows complete resolution of the intraretinal and subretinal fluid, and the patient reports stable visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"wetAMD"}
{"id":2873,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-4822-r.jpg","vqa":{"question":"A patient with the pathology demonstrated in this OCT image returns for follow-up evaluation. The patient reports a progressive decline in visual acuity and new-onset metamorphopsia. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring","B":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Continue strict observation with routine comprehensive eye examinations without intervention"},"answer":"A"},"label":"wetAMD"}
{"id":2935,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-5039-r_001.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up after an initial loading series of injections. Follow-up imaging reveals complete resolution of the subretinal fluid and stable visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"wetAMD"}
{"id":2942,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-5043-r.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up after an initial loading phase of intravitreal injections. The imaging shows complete resolution of the intraretinal and subretinal fluid, and the patient\u0027s visual acuity has stabilized. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval using a treat-and-extend protocol","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","D":"Maintain the current exact treatment protocol and interval without any changes"},"answer":"A"},"label":"wetAMD"}
{"id":2981,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-5157-r_000.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for evaluation after completing an initial loading phase of anti-VEGF injections. Follow-up imaging reveals complete resolution of intraretinal and subretinal fluid with a stabilized foveal contour, and the patient reports stable visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the treatment interval using a treat-and-extend protocol","B":"Switch to an alternative anti-VEGF agent due to the presence of persistent subretinal fluid","C":"Escalate therapy by adding an intravitreal corticosteroid implant to the current regimen","D":"Discharge the patient and recommend routine annual comprehensive eye examinations"},"answer":"A"},"label":"wetAMD"}
{"id":2985,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-5163-l_000.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for evaluation. Follow-up imaging shows complete resolution of the intraretinal and subretinal fluid, and visual acuity has stabilized after the initial loading phase of treatment. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Extend the treatment interval with continued proactive monitoring using a treat-and-extend approach","B":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with routine annual comprehensive eye examinations"},"answer":"A"},"label":"wetAMD"}
{"id":3000,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-5184-r_001.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up after an initial series of intravitreal injections. Follow-up imaging reveals complete resolution of the subretinal fluid and the patient reports stable visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the injection interval using a Treat-and-Extend protocol","B":"Switch to an alternative anti-VEGF agent or intravitreal corticosteroid implant","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling","D":"Discharge the patient to routine annual comprehensive eye examinations without further injections"},"answer":"A"},"label":"wetAMD"}
{"id":3019,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-5207-l_000.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up after completing an initial loading phase of anti-VEGF therapy. Subsequent imaging reveals complete resolution of the intraretinal and subretinal fluid with stable visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring (Treat-and-Extend)","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment","D":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention"},"answer":"A"},"label":"wetAMD"}
{"id":3036,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-5233-r_001.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for follow-up evaluation. The clinician confirms complete resolution of intraretinal and subretinal fluid, and the patient reports stable visual acuity following initial loading anti-VEGF injections. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent edema and initiate prompt retreatment if present","D":"Continue the exact same current protocol and re-evaluate for discharge"},"answer":"A"},"label":"wetAMD"}
{"id":3052,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-5290-r_000.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 4 months later. Follow-up imaging reveals that the subretinal fluid has persisted and worsened despite conservative observation, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch immediately to an intravitreal corticosteroid implant or alternative anti-VEGF agent","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"wetAMD"}
{"id":3079,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-5363-l_001.jpg","vqa":{"question":"A patient presenting with the pathology demonstrated in this OCT image returns for evaluation 3 months later. Follow-up imaging reveals that the subretinal fluid has persisted without any spontaneous resolution, and the patient reports a progressive decline in visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Consider active intervention with photodynamic therapy (PDT) or focal laser photocoagulation","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"wetAMD"}
{"id":3090,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-5385-l_001.jpg","vqa":{"question":"A patient with the condition demonstrated in this OCT image returns for follow-up after receiving an initial loading series of intravitreal anti-VEGF injections. Follow-up imaging reveals complete resolution of the intraretinal and subretinal fluid, and the patient reports stable visual acuity. What is the MOST appropriate next adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval while continuing proactive monitoring using a treat-and-extend protocol","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy due to treatment response","C":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling to restore visual function","D":"Continue strict observation with lifestyle modifications for another 12 months without any further imaging"},"answer":"A"},"label":"wetAMD"}
{"id":3109,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-5424_001.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for evaluation after a series of initial loading injections. Follow-up imaging reveals complete resolution of intraretinal and subretinal fluid, and the patient reports stable visual acuity. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the injection interval with continued proactive monitoring using a treat-and-extend approach","B":"Switch immediately to an alternative anti-VEGF agent or consider an intravitreal corticosteroid implant","C":"Proceed directly to emergency pars plana vitrectomy with internal limiting membrane peeling","D":"Discharge the patient and recommend they return only if they experience a sudden, new onset of visual loss"},"answer":"A"},"label":"wetAMD"}
{"id":3127,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-5522_001.jpg","vqa":{"question":"The patient with the condition demonstrated in this OCT image returns for follow-up. Over the subsequent weeks, the acute retinal edema resolves, transitioning into permanent inner retinal layer thinning and atrophy. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Coordinate long-term care focusing on strict systemic vascular risk factor management and stroke prevention","B":"Extend the anti-VEGF injection interval with continued proactive monitoring","C":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","D":"Continue strict observation with lifestyle modifications for another 12 months without testing"},"answer":"A"},"label":"wetAMD"}
{"id":3152,"image_path":"E:\\OCT\\OCT-Bench\\mmc-amd\\wetAMD\\o-w-ICG-5742-l_001.jpg","vqa":{"question":"The patient with the pathology demonstrated in this OCT image returns for follow-up. Imaging reveals that the intraretinal fluid has completely resolved and visual acuity has stabilized following the initial loading phase. What is the MOST appropriate adjustment to their management strategy?","options":{"A":"Extend the anti-VEGF injection interval with continued proactive monitoring","B":"Switch to an alternative anti-VEGF agent or consider intravitreal corticosteroid implant therapy","C":"Perform repeat OCT imaging to evaluate for recurrent macular edema and initiate prompt anti-VEGF retreatment if present","D":"Recommend surgical intervention with pars plana vitrectomy and epiretinal membrane peeling"},"answer":"A"},"label":"wetAMD"}